Ireland - English - HPRA (Health Products Regulatory Authority)

glaxosmithkline (ireland) limited - zanamivir - inhalation powder, pre-dispensed - 5 milligram(s)/dose - zanamivir

Malta - English - Medicines Authority

glaxo wellcome uk limited - zanamivir - inhalation powder - zanamivir 500 mg - antivirals for systemic use

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - zanamivir - inhalation powder - 5mg

European Union - English - EMA (European Medicines Agency)

glaxosmithkline trading services limited - zanamivir - influenza, human - antivirals for systemic use - dectova is indicated for the treatment of complicated and potentially life-threatening influenza a or b virus infection in adult and paediatric patients (aged ≥6 months) when:the patient’s influenza virus is known or suspected to be resistant to anti-influenza medicinal products other than zanamivir, and/orother anti-viral medicinal products for treatment of influenza, including inhaled zanamivir, are not suitable for the individual patient.dectova should be used in accordance with official guidance.

Malta - English - Medicines Authority

glaxo smithkline ireland limited 12, riverwalk, citywest business campus, dublin 24, ireland - zanamivir - inhalation powder, pre-dispensed - zanamivir 5 µg/dose - antivirals for systemic use

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

glaxo wellcome production - zanamivir - powder for inhalation - 5mg

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - zanamivir micronized - powder for inhalation - zanamivir micronized 5 mg - zanamivir - zanamivir - zanamivir is indicated for the treatment of both uncomplicated acute illness due to influenza a and b virus in adults and adolescents (> or = 12 years) who have been symptomatic for no more than 48 hours and pediatric patients 7 years and older who have been symptomatic for no more than 36 hours.

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - zanamivir micronized - powder for inhalation - zanamivir micronized 5 mg - zanamivir - zanamivir - zanamivir is indicated for the treatment of both uncomplicated acute illness due to influenza a and b virus in adults and adolescents (> or = 12 years) who have been symptomatic for no more than 48 hours and pediatric patients 7 years and older who have been symptomatic for no more than 36 hours.

Singapore - English - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - zanamivir - powder, metered - 5 mg/dose - zanamivir 5 mg/dose

Canada - English - Health Canada

glaxosmithkline inc - zanamivir - powder - 5mg - zanamivir 5mg - neuraminidase inhibitors